(Q42508936)

1 November 2017

title

Basal ganglia hypermetabolism and symptoms of fatigue during interferon-alpha therapy (English)

1 reference

1 November 2017

Bobbi Woolwine

6

0 references

Lucile Capuron

object named as

Lucile Capuron

1

0 references

Giuseppe Pagnoni

object named as

Giuseppe Pagnoni

2

0 references

author name string

Marina F Demetrashvili

3

1 reference

1 November 2017

David H Lawson

4

1 reference

1 November 2017

Fiona B Fornwalt

5

1 reference

1 November 2017

Gregory S Berns

7

1 reference

1 November 2017

Charles B Nemeroff

8

1 reference

1 November 2017

Andrew H Miller

9

1 reference

1 November 2017

language of work or name

English

0 references

publication date

28 February 2007

1 reference

1 November 2017

published in

Neuropsychopharmacology

1 reference

1 November 2017

volume

32

1 reference

1 November 2017

issue

11

1 reference

1 November 2017

page(s)

2384-2392

1 reference

Reproducibility of cerebral glucose metabolic measurements in resting human subjects

1 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301362

Fatigue and proinflammatory cytokine activity in breast cancer survivors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301362

Timing and specificity of the cognitive changes induced by interleukin-2 and interferon-alpha treatments in cancer patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301362

Metabolic correlates of levodopa response in Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301362

The Mini-Mental State Examination.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301362

Pattern of neurobehavioral deficits associated with interferon alfa therapy for leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301362

Regional differences in blood-brain barrier permeability changes and inflammation in the apathogenic clearance of virus from the central nervous system

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301362

HIV Dementia Scale and psychomotor slowing--the best methods in screening for neuro-AIDS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301362

Parallel Organization of Functionally Segregated Circuits Linking Basal Ganglia and Cortex

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301362

7 January 2021

Benign causes of 18-FDG uptake on whole body imaging

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301362

7 January 2021

High opiate receptor binding potential in the human lateral pain system

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301362

7 January 2021

HIV dementia: the role of the basal ganglia and dopaminergic systems

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301362

7 January 2021

Increased depressive ratings in patients with hepatitis C receiving interferon-alpha-based immunotherapy are related to interferon-alpha-induced changes in the serotonergic system

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301362

7 January 2021

Structural and functional neuropathology in transgenic mice with CNS expression of IFN-alpha

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301362

7 January 2021

Neurobehavioral effects of interferon-alpha in cancer patients: phenomenology and paroxetine responsiveness of symptom dimensions.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301362

7 January 2021

Cytokines and psychopathology: lessons from interferon-alpha

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301362

7 January 2021

Interferon-alpha-induced changes in tryptophan metabolism. relationship to depression and paroxetine treatment

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301362

7 January 2021

Anterior cingulate activation and error processing during interferon-alpha treatment

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301362

7 January 2021

Association of exaggerated HPA axis response to the initial injection of interferon-alpha with development of depression during interferon-alpha therapy.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301362

7 January 2021

Association between decreased serum tryptophan concentrations and depressive symptoms in cancer patients undergoing cytokine therapy.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301362

7 January 2021

Fatigue and basal ganglia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301362

7 January 2021

Are the symptoms of cancer and cancer treatment due to a shared biologic mechanism? A cytokine-immunologic model of cancer symptoms

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301362

7 January 2021

AFNI: software for analysis and visualization of functional magnetic resonance neuroimages

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301362

7 January 2021

Cytokine-induced sickness behavior: mechanisms and implications

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301362

7 January 2021

The metabolic topography of parkinsonism

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301362

7 January 2021

Improved Assessment of Significant Activation in Functional Magnetic Resonance Imaging (fMRI): Use of a Cluster‐Size Threshold

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301362

7 January 2021

Microglial activation-mediated delayed and progressive degeneration of rat nigral dopaminergic neurons: relevance to Parkinson's disease.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301362

7 January 2021

Neuroimmunomodulation via limbic structures--the neuroanatomy of psychoimmunology

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301362

7 January 2021

The disclosure of information to cancer patients and its relationship to their mental state in a consultation-liaison psychiatry setting in Japan

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301362

7 January 2021

Prefrontal cortical hypometabolism during low-dose interferon alpha treatment

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301362

7 January 2021

Effect of single intracerebroventricular injection of alpha-interferon on monoamine concentrations in the rat brain

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301362

7 January 2021

Cytokine-induced sickness behaviour: mechanisms and implications

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301362

7 January 2021

Effect of interferon-alpha on tyrosine hydroxylase and catecholamine levels in the brain of rats

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301362

7 January 2021

A cytokine-based neuroimmunologic mechanism of cancer-related symptoms

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301362

7 January 2021

Validity and reliability of a scale to assess fatigue

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301362

7 January 2021

Tumor necrosis factor-alpha receptor ablation in a chronic MPTP mouse model of Parkinson's disease

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301362

7 January 2021

Levodopa improves physical fatigue in Parkinson's disease: A double‐blind, placebo‐controlled, crossover study

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301362

7 January 2021

Exacerbated physical fatigue and mental fatigue in Parkinson's disease

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301362

7 January 2021

Psychopathological symptoms during interferon-alpha and ribavirin treatment: effects on virologic response.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301362

7 January 2021

Reproducibility of cerebral glucose utilization measured by PET and the [18F]-2-fluoro-2-deoxy-d-glucose method in resting, healthy human subjects

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301362

7 January 2021

Selective hypometabolism in the inferior frontal lobe in depressed patients with Parkinson's disease

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301362

7 January 2021

Regulation of neurotransmitter interactions in the ventral striatum

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301362

7 January 2021

Psychometric testing of fatigue instruments for use with cancer patients

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301362

7 January 2021

Relationships among the metabolic patterns that correlate with mnemonic, visuospatial, and mood symptoms in Parkinson's disease

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301362

7 January 2021

Cognitive impairment, fatigue, and cytokine levels in patients with acute myelogenous leukemia or myelodysplastic syndrome

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301362

7 January 2021

Pain, fatigue, and sleep disturbances in oncology outpatients receiving radiation therapy for bone metastasis: a pilot study

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301362

7 January 2021

A New Depression Scale Designed to be Sensitive to Change

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301362

7 January 2021

Paroxetine for the prevention of depression induced by high-dose interferon alfa

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301362

7 January 2021

Inflammatory process in Parkinson's disease: role for cytokines

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301362

7 January 2021

Depression during pegylated interferon-alpha plus ribavirin therapy: prevalence and prediction

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301362

7 January 2021

Cytokines sing the blues: inflammation and the pathogenesis of depression

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301362

7 January 2021

The primate cortico-cerebellar system: anatomy and function

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301362

7 January 2021

Nucleus Accumbens Dopamine and the Regulation of Effort in Food-Seeking Behavior: Implications for Studies of Natural Motivation, Psychiatry, and Drug Abuse

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301362

7 January 2021

Beyond the reward hypothesis: alternative functions of nucleus accumbens dopamine.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301362

7 January 2021

Interferon-induced fatigue in patients with melanoma: a pilot study of exercise and methylphenidate

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301362

7 January 2021

Repeated interferon-alpha administration inhibits dopaminergic neural activity in the mouse brain

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301362

7 January 2021

Visualizing the evolution of abnormal metabolic networks in the brain using PET.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301362

7 January 2021

Intravenous administration of levodopa ameliorated a refractory akathisia case induced by interferon-alpha

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301362

7 January 2021

Potential time course of human immunodeficiency virus type 1-associated minor motor deficits: electrophysiologic and positron emission tomography findings

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301362

7 January 2021

mu- but not delta- and kappa-opioid receptor mediates the nucleus submedius interferon-alpha-evoked antinociception in the rat.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301362

7 January 2021

Oscillations in the basal ganglia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301362

7 January 2021

Microglial localization of α-interferon receptor in human brain tissues

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301362

7 January 2021

Identifiers

DOI

10.1038/SJ.NPP.1301362

1 reference

Dimensions Publication ID

1 November 2017

1050962088

0 references

1 reference